GU Cancers 2024 | Treatment recommendations for high-risk biochemical recurrent prostate cancer

Channing Paller, MD, The Johns Hopkins University, Baltimore, MD, discusses systemic treatment options for patients with high-risk biochemical recurrent prostate cancer. Results from the Phase III EMBARK trial (NCT02319837) of enzalutamide monotherapy, or enzalutamide with leuprolide against placebo and leuprolide demonstrated the efficacy of enzalutamide, which prolonged metastasis-free survival. Despite the findings, matured survival data is needed to evaluate their utility in clinical practice. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.